CXCL9 and Alzheimer disease: This includes reporting a wide range of changes in blood chemokines, such as a 90% higher CXCL10 level, an almost 80% higher CXCL9 level, and 29–35% higher CCL15/CCL27 levels in AD vs controls; an over twice higher CX3CL1 level in MCI vs controls; and an about 130% higher CXCL9 level, 13% lower fractalkine (CX3CL1) level, 37% higher CCL1 level in AD vs MCI.